A Phase 1, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pacritinib in Subjects With Varying Degrees of Hepatic Impairment Compared to Healthy Subjects
Latest Information Update: 23 Oct 2024
Price :
$35 *
At a glance
- Drugs Pacritinib (Primary)
- Indications Graft-versus-host disease; Myelofibrosis
- Focus Pharmacokinetics
- Sponsors CTI BioPharma
- 01 Jul 2024 Status changed from recruiting to completed.
- 23 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 May 2024.
- 23 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 May 2024.